Table 2 BCVA and visual field examination data of retinitis pigmentosa (RP) patients at baseline, 1 month, 3 months and 6 months

BCVA logMAR

Treated eye

Median (IQR)

1.30 (1.00–2.00)^a

1.00 (0.50–1.30)^ab

0.80 (0.40–1.30)^b

0.80 (0.40–1.30)^b

Mean ± SD

1.38 ± 0.68

1.02 ± 0.60

0.94 ± 0.56

0.89 ± 0.58

Fellow eye

Median (IQR)

1.00 (0.70–2.00)

1.30 (0.50–2.00)

1.60 (0.60–2.50)

1.60 (0.70–2.50)

Mean ± SD

1.42 ± 0.91

1.38 ± 0.96

1.56 ± 1.02

1.59 ± 1.00

p

0.888**

0.413***

0.068**

0.039**

MD 30/2

Treated eye

Median (IQR)

32.2 (30.4–32.8)^a

31.5 (29.1–32.6)^ab

31.6 (19.9–32.4)^ab

30.6 (27.1–32.5)^b

Mean ± SD

31.2 ± 3.3

30.8 ± 2.0

31.0 ± 1.9

28.2 ± 8.0

Fellow eye

Median (IQR)

32.3 (30.3–33.8)

31.9 (30.3–33.6)

32.4 (30.4–33.8)

32.2 (31.3–34.7)

Mean ± SD

32.0 ± 2.1

31.9 ± 2.3

32.3 ± 1.9

32.6 ± 1.8

p

0.829***

0.215**

0.132**

0.051***

PSD 30/2

Treated eye

Median (IQR)

3.4 (1.6–5.6)

4.0 (2.1–6.0)

4.8 (2.7–5.6)

4.6 (2.7–5.6)

Mean ± SD

3.7 ± 1.8

4.1 ± 1.9

4.1 ± 1.7

4.5 ± 1.9

Fellow eye

Median (IQR)

3.7 (1.7–6.2)

3.8 (1.5–5.4)

3.5 (1.8–5.6)

3.3 (2.0–4.9)

Mean ± SD

3.7 ± 2.2

3.5 ± 2.0

3.8 ± 2.4

3.6 ± 2.0

p

0.997**

0.465**

0.753**

0.300**

MD 10/2

Treated eye

Median (IQR)

27.7 (25.2–34.3)^a

26.3 (21.8–34.3)^ab

26.1 (21.0–34.2)^ab

28.7 (21.6–34.3)^b

Mean ± SD

28.7 ± 5.0

27.7 ± 5.7

27.5 ± 6.0

28.0 ± 6.6

Fellow eye

Median (IQR)

30.8 (22.0–32.1)

30.9 (23.8–32.7)

31.6 (27.2–32.9)

30.0 (25.9–31.6)

Mean ± SD

28.0 ± 5.0

28.6 ± 5.0

30.3 ± 3.8

29.1 ± 2.6

p

0.882***

1.000***

0.417***

1.000***

PSD 10/2

Treated eye

Median (IQR)

5.5 (3.0–6.1)^ab

4.7 (2.3–6.0)^ab

4.8 (1.5–5.3)^a

5.0 (1.7–6.3)^b

Mean ± SD

4.8 ± 2.0

4.2 ± 2.0

3.9 ± 2.3

4.3 ± 2.3

Fellow eye

Median (IQR)

5.7 (4.2–6.1)

5.2 (4.1–6.3)

5.0 (3.5–6.0)

4.9 (3.5–6.7)

Mean ± SD

5.1 ± 1.7

5.1 ± 1.7

4.5 ± 1.6

4.7 ± 2.0

P

0.882***

0.331***

0.470***

0.867***